The pathogenesis and treatment of the ‘Cytokine Storm' in COVID-19

Journal of Infection

Volumn 80, Issue 6, 2020, Pages 607-613

  Ye, Qing ^a   Wang, Bili ^a   Mao, Jianhua ^a  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

2019 nCoV; Coronavirus; Cytokine storm; Immunomodulation; SARS CoV 2

Indexed keywords

CHLOROQUINE; CORTICOSTEROID; ERITORAN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; INTERFERON; INTERFERON LAMBDA; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; SIPONIMOD; SMALL INTERFERING RNA; TOCILIZUMAB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ULINASTATIN; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT;

BLOOD VESSEL PERMEABILITY; CORONAVIRUS DISEASE 2019; CRITICALLY ILL PATIENT; CYTOKINE STORM; HEMODIALYSIS; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE UNIT; MACROPHAGE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; BETACORONAVIRUS; COMPLICATION; CORONAVIRUS INFECTION; CRITICAL ILLNESS; CYTOKINE RELEASE SYNDROME; IMMUNOLOGY; PANDEMIC; PATHOPHYSIOLOGY; VIRUS PNEUMONIA;

ANTI-INFLAMMATORY AGENTS; BETACORONAVIRUS; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; CYTOKINE RELEASE SYNDROME; HUMANS; PANDEMICS; PNEUMONIA, VIRAL;

EID: 85083268551     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2020.03.037     Document Type: Review

References (95)

1. Lai, C.-C., Shih, T.-P., Ko, W.-C., Tang, H.-J., Hsueh, P.-R., Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents, 2020, 105924 2020/02/17/.
2. Special Expert Group for Control of the Epidemic of Novel Coronavirus Pneumonia of the Chinese Preventive Medicine Association. An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19). Chin J Epidemiol, 2020, 41.
3. Chousterman, B.G., Swirski, F.K., Weber, G.F., Cytokine storm and sepsis disease pathogenesis. Seminars Immunopathol 39:5 (2017), 517–528 2017/07/01.
4. Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H.J., Schlößer, H.A., Schlaak, M., et al. Cytokine release syndrome. J ImmunoTherapy Cancer, 6(1), 2018, 56 2018/06/15.
5. Wan S., Yi Q., Fan S., Lv J., Zhang X., Guo L., et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). 2020:medRxiv2020.02.10.20021832.
6. Peck, K.M., Burch, C.L., Heise, M.T., Baric, R.S., Coronavirus host range expansion and middle east respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives. Ann Rev Virol 2:1 (2015), 95–117 PubMed PMID: 26958908. Epub 2015/08/07. eng.
7. Su, S., Wong, G., Shi, W., Liu, J., Lai, A.C.K., Zhou, J., et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 24:6 (Jun 2016), 490–502 PubMed PMID: 27012512. Epub 2016/03/26. eng.
8. Weiss, S.R., Navas-Martin, S., Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69:4 (Dec 2005), 635–664 PubMed PMID: 16339739. Pubmed Central PMCID: PMC1306801. Epub 2005/12/13. eng.
9. Perlman, S., Netland, J., Coronaviruses post-SARS: update on replication and pathogenesis. Nature Rev Microbiol 7:6 (2009), 439–450 PubMed PMID: 19430490. eng.
10. Heugel, J., Martin, E.T., Kuypers, J., Englund, J.A., Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Disease J 26:8 (2007), 753–755 PubMed PMID: 17848893. eng.
11. Kuypers, J., Martin, E.T., Heugel, J., Wright, N., Morrow, R., Englund, J.A., Clinical disease in children associated with newly described coronavirus subtypes. Pediatrics 119:1 (2007), e70–ee6 PubMed PMID: 17130280. Epub 2006/11/27. eng.
12. Kuiken, T., Fouchier, R.A.M., Schutten, M., Rimmelzwaan, G.F., van Amerongen, G., van Riel, D., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362:9380 (2003), 263–270 (London, England)PubMed PMID: 12892955. eng.
13. Peiris, J.S.M., Lai, S.T., Poon, L.L.M., Guan, Y., Yam, L.Y.C., Lim, W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:9366 (2003), 1319–1325 (London, England)PubMed PMID: 12711465. eng.
14. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D.M.E., Fouchier, R.A.M., Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. Engl J Med 367:19 (2012), 1814–1820 PubMed PMID: 23075143. Epub 2012/10/17. eng.
15. Channappanavar, R., Fehr, A.R., Vijay, R., Mack, M., Zhao, J., Meyerholz, D.K., et al. Dysregulated Type I Interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 19:2 (2016), 181–193 PubMed PMID: 26867177. eng.
16. Davidson, S., Maini, M.K., Wack, A., Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J Interf Cytokine Res Offic J Int Soc Interf Cytokine Res 35:4 (2015), 252–264 PubMed PMID: 25714109. Epub 2015/02/25. eng.
17. Shaw, A.C., Goldstein, D.R., Montgomery, R.R., Age-dependent dysregulation of innate immunity. Nature Rev Immunol 13:12 (2013), 875–887 PubMed PMID: 24157572. Epub 2013/10/25. eng.
18. Law, H.K.W., Cheung, C.Y., Ng, H.Y., Sia, S.F., Chan, Y.O., Luk, W., et al. Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood 106:7 (2005), 2366–2374 PubMed PMID: 15860669. Epub 2005/04/28. eng.
19. Cheung, C.Y., Poon, L.L.M., Ng, I.H.Y., Luk, W., Sia, S.-F., Wu, M.H.S., et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J Virol 79:12 (2005), 7819–7826 PubMed PMID: 15919935. eng.
20. Lau, S.K.P., Lau, C.C.Y., Chan, K.-H., Li, C.P.Y., Chen, H., Jin, D.-Y., et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 94:Pt 12 (2013), 2679–2690 PubMed PMID: 24077366. Epub 2013/09/28. eng.
21. Tynell, J., Westenius, V., Rönkkö, E., Munster, V.J., Melén, K., Österlund, P., et al. Middle East respiratory syndrome coronavirus shows poor replication but significant induction of antiviral responses in human monocyte-derived macrophages and dendritic cells. J Gen Virol 97:2 (2016), 344–355 PubMed PMID: 26602089. Epub 2015/11/24. eng.
22. Zhou, J., Chu, H., Li, C., Wong, B.H.-Y., Cheng, Z.-S., Poon, V.K.-M., et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Diseases 209:9 (2014), 1331–1342 PubMed PMID: 24065148. Epub 2013/09/24. eng.
23. Scheuplein, V.A., Seifried, J., Malczyk, A.H., Miller, L., Höcker, L., Vergara-Alert, J., et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol 89:7 (2015), 3859–3869 PubMed PMID: 25609809. Epub 2015/01/21. eng.
24. Kim, E.S., Choe, P.G., Park, W.B., Oh, H.S., Kim, E.J., Nam, E.Y., et al. Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection. J Korean Med Sci 31:11 (2016), 1717–1725 PubMed PMID: 27709848. eng.
25. Min, C.-K., Cheon, S., Ha, N.-Y., Sohn, K.M., Kim, Y., Aigerim, A., et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Scient Rep, 6, 2016, 25359 PubMed PMID: 27146253. eng.
26. Ng, D.L., Al Hosani, F., Keating, M.K., Gerber, S.I., Jones, T.L., Metcalfe, M.G., et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the United Arab Emirates, April 2014. Am J Pathol 186:3 (2016), 652–658 PubMed PMID: 26857507. Epub 2016/02/05. eng.
27. JY, C., PR, H., WC, C., CJ, Y., PC, Y., Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirol (Carlton, Vic) 11:6 (2006), 715–722 PubMed PMID: 17052299.
28. CH, W., CY, L., YL, W., CL, C., KH, H., HC, L., et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respirat Res, 6, 2005, 42 PubMed PMID: 15888207.
29. CK, W., CW, L., AK, W., WK, I., NL, L., IH, C., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exper Immunol 136:1 (2004), 95–103 PubMed PMID: 15030519.
30. Y, Z., J, L., Y, Z., L, W., X, Y., W, Z., et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 72:8 (2004), 4410–4415 PubMed PMID: 15271897.
31. Chien, J.-Y., Hsueh, P.-R., Cheng, W.-C., Yu, C.-J., Yang, P.-C., Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirol (Carlton, Vic) 11:6 (2006), 715–722 PubMed PMID: 17052299. eng.
32. Wang, C.-H., Liu, C.-Y., Wan, Y.-L., Chou, C.-L., Huang, K.-H., Lin, H.-C., et al. Persistence of lung inflammation and lung cytokines with high-resolution CT abnormalities during recovery from SARS. Respirat Res, 6(1), 2005, 42 -. PubMed PMID: 15888207. eng.
33. Wong, C.K., Lam, C.W.K., Wu, A.K.L., Ip, W.K., Lee, N.L.S., Chan, I.H.S., et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical Exper Immunol 136:1 (2004), 95–103 PubMed PMID: 15030519. eng.
34. Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 72:8 (2004), 4410–4415 PubMed PMID: 15271897. eng.
35. A, G.-S., CA, B., Type 1 interferons and the virus-host relationship: a lesson in détente. Science 312:5775 (2006), 879–882 (New York, NY)PubMed PMID: 16690858.
36. R, C., AR, F., J, Z., C, W.-L., JE, A., M, M., et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest 130 (2019), 3625–3639 PubMed PMID: 31355779.
37. Smits, S.L., de Lang, A., van den Brand, J.M.A., Leijten, L.M., van Ijcken, W.F., Eijkemans, M.J.C., et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathogens, 6(2), 2010 e1000756-e. PubMed PMID: 20140198. eng.
38. Rockx, B., Baas, T., Zornetzer, G.A., Haagmans, B., Sheahan, T., Frieman, M., et al. Early upregulation of acute respiratory distress syndrome-associated cytokines promotes lethal disease in an aged-mouse model of severe acute respiratory syndrome coronavirus infection. J Virol 83:14 (2009), 7062–7074 PubMed PMID: 19420084. Epub 2009/05/06. eng.
39. Herold, S., Steinmueller, M., von Wulffen, W., Cakarova, L., Pinto, R., Pleschka, S., et al. Lung epithelial apoptosis in influenza virus pneumonia: the role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exper Med 205:13 (2008), 3065–3077 PubMed PMID: 19064696. Epub 2008/12/08. eng.
40. Högner, K., Wolff, T., Pleschka, S., Plog, S., Gruber, A.D., Kalinke, U., et al. Macrophage-expressed IFN-β contributes to apoptotic alveolar epithelial cell injury in severe influenza virus pneumonia. PLoS Pathogens, 9(2), 2013 e1003188-e. PubMed PMID: 23468627. Epub 2013/02/28. eng.
41. Rodrigue-Gervais, I.G., Labbé, K., Dagenais, M., Dupaul-Chicoine, J., Champagne, C., Morizot, A., et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe 15:1 (2014), 23–35 PubMed PMID: 24439895. eng.
42. Drosten, C., Seilmaier, M., Corman, V.M., Hartmann, W., Scheible, G., Sack, S., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Diseases 13:9 (2013), 745–751 PubMed PMID: 23782859. Epub 2013/06/17. eng.
43. Lew, T.W.K., Kwek, T.-K., Tai, D., Earnest, A., Loo, S., Singh, K., et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290:3 (2003), 374–380 PubMed PMID: 12865379. eng.
44. Jiang, Y., Xu, J., Zhou, C., Wu, Z., Zhong, S., Liu, J., et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respirat Critical Care Med 171:8 (2005), 850–857 PubMed PMID: 15657466. Epub 2005/01/18. eng.
45. Reghunathan, R., Jayapal, M., Hsu, L.-Y., Chng, H.-H., Tai, D., Leung, B.P., et al. Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol, 6, 2005, 2 -. PubMed PMID: 15655079. eng.
46. Cameron, M.J., Bermejo-Martin, J.F., Danesh, A., Muller, M.P., Kelvin, D.J., Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 133:1 (2008), 13–19 PubMed PMID: 17374415. Epub 2007/03/19. eng.
47. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:10223 (2020), 497–506 2020/02/15/.
48. Marchingo, J.M., Sinclair, L.V., Howden, A.J.M., Cantrell, D.A., Quantitative analysis of how Myc controls T cell proteomes and metabolic pathways during T cell activation. eLife., 9, 2020, e53725 2020/02/05.
49. Chen, L., Liu, H.-G., Liu, W., Liu, J., Liu, K., Shang, J., et al. Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia. Chin J Tuberc Respir Dis, 43, 2020.
50. Yang, X., Yu, Y., Xu, J., Shu, H., Ja, X.i.a., Liu, H., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respirat Med, 2020 S2213-600(20)30079-5. PubMed PMID: 32105632. eng.
51. Force* TADT. Acute respiratory distress syndrome: the berlin definition. JAMA 307:23 (2012), 2526–2533.
52. Douda, D.N., Jackson, R., Grasemann, H., Palaniyar, N., Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. J Immunol (Baltimore, Md: 1950) 187:4 (2011), 1856–1865 PubMed PMID: 21724991. Epub 2011/07/01. eng.
53. Parsons, P.E., Eisner, M.D., Thompson, B.T., Matthay, M.A., Ancukiewicz, M., Bernard, G.R., et al. Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Critical Care Med 33:1 (2005), 1–232 PubMed PMID: 15644641. eng.
54. Wang, H., Ma, S., The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 26:6 (2008), 711–715 PubMed PMID: 18606328. eng.
55. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med, 3(9), 2006 e343-e. PubMed PMID: 16968120. eng.
56. Arabi, Y.M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clinical Infect Diseas Offic Publ Infect Diseases Soc Am, 2019 ciz544. PubMed PMID: 31925415. eng.
57. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nature Med 19:10 (2013), 1313–1317 PubMed PMID: 24013700. Epub 2013/09/08. eng.
58. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Inf Diseases 14:11 (2014), 1090–1095 PubMed PMID: 25278221. Epub 2014/09/29. eng.
59. Davidson, S., McCabe, T.M., Crotta, S., Gad, H.H., Hessel, E.M., Beinke, S., et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Molecul Med 8:9 (2016), 1099–1112 PubMed PMID: 27520969. eng.
60. Blazek, K., Eames, H.L., Weiss, M., Byrne, A.J., Perocheau, D., Pease, J.E., et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J Exper Med 212:6 (2015), 845–853 PubMed PMID: 25941255. Epub 2015/05/04. eng.
61. Arabi, Y.M., Shalhoub, S., Mandourah, Y., Al-Hameed, F., Al-Omari, A., Al Qasim, E., et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clinical Infect Diseases, 2019.
62. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Diseases 14:11 (2014), 1090–1095 2014/11/01/.
63. Zumla, A., Chan, J.F.W., Azhar, E.I., Hui, D.S.C., Yuen, K.-Y., Coronaviruses — drug discovery and therapeutic options. Nature Rev Drug Discov 15:5 (2016), 327–347 2016/05/01.
64. Auyeung, T.W., Lee, J.S.W., Lai, W.K., Choi, C.H., Lee, H.K., Lee, J.S., et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect 51:2 (2005), 98–102 PubMed PMID: 16038758. eng.
65. Ho, J.C., Ooi, G.C., Mok, T.Y., Chan, J.W., Hung, I., Lam, B., et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Resp Crit Care Med 168:12 (2003), 1449–1456 PubMed PMID: 12947028. Epub 2003/08/28. eng.
66. Yam, L.Y.-C., Lau, A.C.-W., Lai, F.Y.-L., Shung, E., Chan, J., Wong, V., et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect 54:1 (2007), 28–39 PubMed PMID: 16542729. Epub 2006/03/15. eng.
67. Chen, R.-c., Tang, X.-p., Tan, S.-y., Liang, B.-l., Wan, Z.-y., Fang, J.-q., et al. Treatment of Severe Acute Respiratory Syndrome With Glucosteroids: The Guangzhou Experience. Chest 129:6 (2006), 1441–1452 2006/06/01/.
68. Zhao, J.-p., Hu, Y., Du, R.-h., Chen, Z.-s., Jin, Y., Zhou, M., et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Chin J Tuberc Respir Dis(00), 2020 E007-E. chi.
69. Zhou, Y.-H., Qin, Y.-Y., Lu, Y.-Q., Sun, F., Yang, S., Harypursat, V., et al. Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J(00), 2020 E020-E. chi.
70. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395:10223 (2020), 507–513 2020/02/15/.
71. Shakoory, B., Carcillo, J.A., Chatham, W.W., Amdur, R.L., Zhao, H., Dinarello, C.A., et al. Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Critical Care Med 44:2 (2016), 275–281 PubMed PMID: 26584195. eng.
72. Biggioggero, M., Crotti, C., Becciolini, A., Favalli, E.G., Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. Drug Design, Devel Therapy 13 (2018), 57–70 PubMed PMID: 30587928. eng.
73. Tanaka, T., Narazaki, M., Kishimoto, T., Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8:8 (2016), 959–970 PubMed PMID: 27381687. eng.
74. Qiu, P., Cui, X., Sun, J., Welsh, J., Natanson, C., Eichacker, P.Q., Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. Critical Care Med 41:10 (2013), 2419–2429 PubMed PMID: 23887234. eng.
75. Udalova, I., Monaco, C., Nanchahal, J., Feldmann, M., Anti-TNF Therapy. Microbiol Spect, 4(4), 2016.
76. McDermott, J.E., Mitchell, H.D., Gralinski, L.E., Eisfeld, A.J., Josset, L., Bankhead, A., et al. The effect of inhibition of PP1 and TNFα signaling on pathogenesis of SARS coronavirus. BMC Syst Biol, 10(1), 2016, 93 -. PubMed PMID: 27663205. eng.
77. J, G., Z, T., X, Y., Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14:1 (2020), 72–73 PubMed PMID: 32074550.
78. multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Chinese J Tubercul Respirat Diseases, 43, 2020 E019-E. PubMed PMID: 32075365.
79. H, W., B, L., Y, T., P, C., L, Y., B, H., et al. Improvement of sepsis prognosis by Ulinastatin: a systematic review and meta-analysis of randomized controlled trials. Frontiers Pharmacol, 10, 2019, 1370 PubMed PMID: 31849646.
80. M, J., H, H., S, C., Y, L., Y, L., S, P., et al. Ulinastatin ameliorates LPS-induced pulmonary inflammation and injury by blocking the MAPK/NF-κB signaling pathways in rats. Molecul Med Rep 20:4 (2019), 3347–3354 PubMed PMID: 31432172.
81. Imai, Y., Kuba, K., Neely, G.G., Yaghubian-Malhami, R., Perkmann, T., van Loo, G., et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133:2 (2008), 235–249 PubMed PMID: 18423196. eng.
82. Shirey, K.A., Perkins, D.J., Lai, W., Zhang, W., Fernando, L.R., Gusovsky, F., et al. Influenza "Trains" the host for enhanced susceptibility to secondary bacterial infection. mBio. 10:3 (2019), e00810–e00819 PubMed PMID: 31064834. eng.
83. Maceyka, M., Harikumar, K.B., Milstien, S., Spiegel, S., Sphingosine-1-phosphate signaling and its role in disease. Trends Cell Biol 22:1 (2012), 50–60 PubMed PMID: 22001186. Epub 2011/10/14. eng.
84. Walsh, K.B., Teijaro, J.R., Rosen, H., Oldstone, M.B.A., Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res, 51(1), 2011, 15 2011/09/08.
85. Teijaro, J.R., Walsh, K.B., Cahalan, S., Fremgen, D.M., Roberts, E., Scott, F., et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:6 (2011), 980–991 PubMed PMID: 21925319. eng.
86. Walsh, K.B., Teijaro, J.R., Wilker, P.R., Jatzek, A., Fremgen, D.M., Das, S.C., et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA 108:29 (2011), 12018–12023 PubMed PMID: 21715659. Epub 2011/06/29. eng.
87. Uccelli, A., de Rosbo, N.K., The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann NY Acad Sci 1351:1 (2015), 114–126.
88. Ben-Mordechai, T., Palevski, D., Glucksam-Galnoy, Y., Elron-Gross, I., Margalit, R., Leor, J., Targeting macrophage subsets for infarct repair. J Cardiovascular Pharmacol Therapeut 20:1 (2014), 36–51 2015/01/01.
89. Lee, J.W., Fang, X., Krasnodembskaya, A., Howard, J.P., Matthay, M.A., Concise review: Mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. STEM CELLS 29:6 (2011), 913–919.
90. K, X., H, C., Y, S., Q, N., Y, C., S, H., et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue xue bao Yi xue ban, 49(1), 2020, 0 PubMed PMID: 32096367.
91. Zuccari, S., Damiani, E., Domizi, R., Scorcella, C., D'Arezzo, M., Carsetti, A., et al. Changes in cytokines, haemodynamics and microcirculation in patients with sepsis/septic shock undergoing continuous renal replacement therapy and blood purification with cytoSorb. Blood Purificat 49:1-2 (2020), 107–113.
92. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respirat Med, 2020 S2213-600(20)30076-X. PubMed PMID: 32085846. eng.
93. Leuschner, F., Courties, G., Dutta, P., Mortensen, L.J., Gorbatov, R., Sena, B., et al. Silencing of CCR2 in myocarditis. Eur Heart J 36:23 (2015), 1478–1488 PubMed PMID: 24950695. Epub 2014/06/20. eng.
94. Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T.I., Donahoe, J.S., Courties, G., et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nature Biotechnol 29:11 (2011), 1005–1010 PubMed PMID: 21983520. eng.
95. London, N.R., Zhu, W., Bozza, F.A., Smith, M.C.P., Greif, D.M., Sorensen, L.K., et al. Targeting Robo4-Dependent Slit Signaling to Survive the Cytokine Storm in Sepsis and Influenza. Sci Transl Med, 2(23), 2010 23ra19.